Total Voting Rights and Admission of Shares

Summary by AI ^BETAClose X

AstraZeneca PLC has announced that as of March 31, 2026, its total voting rights stand at 1,550,980,823 ordinary shares, with no shares held in treasury. The company also reported the admission of 491 further ordinary shares of $0.25 each to trading on the London Stock Exchange's Main Market, bringing the total issued securities to 1,550,980,823. These newly admitted shares, issued between March 20 and March 31, 2026, under employee share schemes, are fully fungible with existing ordinary shares.

Disclaimer*

AstraZeneca PLC

01 April 2026

1 April 2026

Total Voting Rights and Notification of Admission of Further Securities to Trading (PRM 1.6.4R)

Total Voting Rights

The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. As at 31 March 2026 the issued share capital of AstraZeneca PLC with voting rights is 1,550,980,823 ordinary shares of US$0.25. No shares are held in Treasury. Therefore, the total number of voting rights in AstraZeneca PLC is 1,550,980,823.

The above figure for the total number of voting rights may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, AstraZeneca PLC under the UK Financial Conduct Authority's Disclosure and Transparency Rules.

Notification of Admission of Further Securities to Trading (PRM 1.6.4R)

The following notification is made in accordance with The Public Offers and Admissions to Trading Regulations 2024 (POATRs) PRM 1.6.4R.

1	Details of the issuer
a)	Name	AstraZeneca PLC
b)	LEI	PY6ZZQWO2IZFZC3IOL08
2	Details of the transferable securities admitted to trading
a)	Name, type and identification code	Ordinary Shares of $0.25 each ISIN: GB0009895292
b)	Regulated market	London Stock Exchange - Main Market
c)	Number of further securities issued and admitted	491
d)	Total number of securities in issue following admission	1,550,980,823
e)	Fungibility	Fully fungible with existing Ordinary Shares
3	Admission details
a)	Date of admission	Issued between 20 March 2026 to 31 March 2026 (admitted under a block admission dated 29 January 2021)
b)	Prospectus information	Prospectus: N/A Supplementary: N/A Company's webpage: https://www.astrazeneca.com
c)	Coverage of notification	Admission of shares under the Company's employee share schemes from 20 March 2026 up to 31 March 2026, admitted to trading on the Main Market of the London Stock Exchange under the Company's existing block admission of shares dated 29 January 2021.

AstraZeneca

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

Matthew Bowden
Company Secretary

AstraZeneca PLC

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END